Tempus AI (TEM) said Tuesday that results of a new study show that its Immune Profile Score algorithmic test predicts outcomes for patients receiving immune checkpoint inhibitors more accurately than conventional biomarkers.

The company said the results show that the test "consistently" outperformed conventional biomarkers, and can help physicians identify the patients who are most likely to benefit from immunotherapy.

Tempus shares were 0.7% higher in recent trading.